CSIWM 个股点评 2026 年 2 月 27 日 药明生物 2269 HK 中国医疗保健行业 电话：(852) 2237 9250 / 电邮：wminvestmentsolutions@citics.com.hk 抛售：资金流动驱动，非基本面因素 摘要 中信证券财富管理与中信里昂研究观点一致。根据中信里昂研究在 2026 年 2 月 26 日发布的题为《Sell-off: Flow-led, not fundamentals》 的 报 告 ， 药 明 生 物 （ WuXi Biologics） 及 其 子 公 司 药 明 合 联 （ WuXi XDC） 今 日 分 别 下 跌 约 7%/8%，而香港上市 CRO/CDMO 板块整体下跌 2-9%。中信里昂认为这些波动并非基本面驱动，更多可能是仓位 调整和资金流动所致。 三月指引季或成下一个催化因素 催化因素 (1) 双/多特异性药物引领的项目动能，有望推动2026 年收入重新加速增长；(2) 2025 年新增项目数超预期（净增128 个项目，超越市场预期），为 2026 年预期增速快于 2025 年奠定基础；(3) 地缘政治估值折价因素消退，2026 年该 ...

按照北京城市总体规划，平原新城是指顺义、大兴、亦庄、昌平、房山的新城及地区，是首都面向区域 协同发展的重要战略门户，是承接中心城区适宜功能、服务保障首都功能的重点地区，也是构建现代化 首都都市圈的重要一环。 日前，由北京市、天津市、河北省联合编制的《现代化首都都市圈空间协同规划（2023—2035年）》 （以下简称《规划》）发布，《规划》提出，全面提升平原新城综合承载能力。实施战略赋能，依托资 源禀赋，抢抓发展先机，打造特色鲜明、有影响力的新城名片。实施要素赋能，围绕产业链统筹布局人 才链，营造良好人才生态和发展环境，加大人才、资金、土地等要素倾斜支持，提升资源配置能力。实 施功能赋能，打造便捷高效的交通通道，加快布局优质教育、医疗、养老、托育等公共服务资源。实施 政策赋能，加强用地功能兼容与建筑复合利用。 为将提升平原新城综合承载能力的部署落到实处，破解各区发展难题，推动政策红利精准释放，2025年 初，北京市政府根据各平原新城特点和实际，"一区一策"批复了各具特色的高质量发展实施方案，进一 步明确了平原新城各区发展定位、发展目标和具体任务。顺义区聚焦国际化水平提升，重点建设临空经 济先行区、产城融合国际新 ...

Group 1 - The core viewpoint emphasizes the need for banks to transition from traditional lending practices to a more nuanced approach that supports technological innovation through precise financial support [1][6] - The shift in banking strategy involves moving from reliance on hard assets to understanding the potential of soft assets, requiring banks to assess future growth rather than just past performance [1][2] - Banks are increasingly adopting digital tools to identify potential technology companies, marking a consensus among many banks to upgrade their technology financial service models [1][2] Group 2 - The role of banks is evolving from being mere fund providers to becoming partners in the market, supporting technology companies throughout their growth journey [3][4] - Banks are implementing comprehensive financial service models that combine online and offline approaches to meet the financing needs of technology enterprises, particularly those with high development potential [2][3] - Collaborative ecosystems are being developed where banks not only provide loans but also connect technology companies with industry resources and investment opportunities [3][4] Group 3 - A systemic transformation within banks is necessary to create a long-term mechanism that encourages lending to technology companies, focusing on risk pricing, organizational structure, and incentive systems [5][6] - The current challenges in technology finance stem from mismatches between the needs of technology companies and traditional banking models, necessitating a shift in risk assessment and service collaboration [5][6] - The future of banking in the context of technology finance will involve creating a diverse ecosystem that includes government, investment institutions, and other stakeholders to enhance support for innovation [6]

Core Viewpoint - Jinan aims to implement an industrial strong city strategy by 2026, focusing on building a modern industrial system Group 1: Strengthening Advantageous Industries - The city will focus on electronic information, automotive, high-end software, and modern medicine industries, aiming to enhance scale, extend chains, and grow enterprises [2] - In the electronic information sector, Jinan plans to achieve an industry scale of 240 billion yuan by accelerating the construction of semiconductor and micro-display projects [2] - The automotive industry aims for a scale of 180 billion yuan, supporting companies like BYD and Geely in introducing high-end models and promoting collaborative development [2] - The high-end software sector targets a scale of 130 billion yuan, emphasizing the development of industrial software and AI applications [2] - The modern medicine industry, relying on key enterprises, aims for a scale of 52 billion yuan by enhancing various pharmaceutical sectors [2] Group 2: Cultivating Characteristic Industries - Jinan will focus on high-end CNC machine tools, robotics, specialized equipment, steel, advanced materials, and food and bio-manufacturing, aiming to create competitive industrial clusters [4] - The high-end CNC machine tools and robotics sector targets a scale of 55 billion yuan, with key projects like the industrial mother machine park [4] - The specialized equipment industry aims for a scale of 115 billion yuan, with support for leading companies and project expansions [4] - The steel industry will focus on green low-carbon transformation, targeting a scale of 165 billion yuan by developing high-value products [4] - The advanced materials sector aims for a scale of 35 billion yuan, promoting innovation and expansion in chemical and metal materials [4] - The food and bio-manufacturing industry targets a scale of 77.5 billion yuan, supporting innovative development of key enterprises [4]

Core Insights - The biopharmaceutical industry in China is a strategic emerging industry, crucial for public health, technological innovation, and enhancing national pharmaceutical autonomy. The market size is projected to grow from CNY 4,210 billion in 2022 to CNY 8,000 billion by 2028, with an annual growth rate stabilizing between 10%-12% [1][2][23]. Industry Overview - In 2020, the biopharmaceutical market in China was valued at CNY 3,457 billion, increasing to CNY 4,100 billion in 2021, representing an 18.6% year-on-year growth. However, growth slowed to 2.68% in 2022, with a slight increase to CNY 4,210 billion [1][2]. - The industry is segmented into upstream (raw materials and medical devices), midstream (drug synthesis and production), and downstream (drug distribution). Biopharmaceuticals and chemical drugs have higher profit margins, with biopharmaceutical companies reporting gross margins of 80%-86% [2][4]. Xiamen Biopharmaceutical Industry - Xiamen is a key hub for biopharmaceutical industry development, recognized as a national strategic emerging industry cluster. The local government has implemented various supportive policies since 2016, focusing on innovation and industrialization [6][9]. - The industrial output value of Xiamen's biopharmaceutical sector reached CNY 1,045.87 billion in 2022, with a slight decline to CNY 847 billion in 2023, and is projected to stabilize around CNY 840 billion in 2024 [17][18]. Policy Environment - Xiamen's government has introduced multiple measures to support the biopharmaceutical industry, including financial incentives for R&D and commercialization, with significant rewards for new drug development and medical device innovation [9][26]. - The city aims to establish a CNY 100 billion venture capital fund and enhance the entire process from R&D to clinical application by 2025 [23][26]. Future Outlook - By 2025, Xiamen plans to significantly increase the number of registered biopharmaceutical companies, with projections indicating over 2,200 registered firms, marking a notable rise from previous years [18]. - The city aims to develop a CNY 700 billion biopharmaceutical industry chain, supported by specialized parks and a focus on various sub-sectors, including biopharmaceuticals and medical devices [23][26].

Core Viewpoint - Chutian Technology (300358) is expected to return to profit growth in 2025, with projected net profit ranging from 235 million to 300 million yuan, following a loss of 453 million yuan in the previous year [1] Group 1: Financial Performance - The company anticipates a net profit of 135 million to 200 million yuan after excluding non-recurring gains and losses for 2025 [1] - For the first three quarters, Chutian Technology reported operating revenue of 3.896 billion yuan and a net profit attributable to shareholders of 84.46 million yuan, estimating a fourth-quarter net profit of 151 million to 215 million yuan [1] Group 2: Growth Drivers - The growth in performance is attributed to international market expansion, improved order quality, and cost reduction measures [1][2] - The company has seen a significant increase in the quality and gross margin of new order contracts during the reporting period [1] - Non-recurring gains and losses are expected to impact the 2025 net profit by approximately 100 million yuan [1] Group 3: International Market Expansion - Chutian Technology is intensifying its efforts in international market expansion, achieving breakthroughs in Southeast Asia, the Middle East, Africa, and the Americas, leading to a significant increase in the proportion of international business [1][2] - The company has segmented the global market into five regions to enhance local sales and service responsiveness [2] Group 4: Operational Strategies - Starting from the second half of 2024, the company will implement a differentiated competition strategy to enhance order quality and has initiated various cost reduction measures [2] - The company is optimizing product solutions in R&D, reducing procurement costs in the supply chain, and improving production efficiency, which has led to a noticeable increase in gross margin [2] - A series of refined management measures have been implemented to control overall operating costs, with total expenses significantly reduced compared to the previous year [2] Group 5: Future Outlook - Chutian Technology plans to continue expanding its overseas market presence while capitalizing on the growth and high-end transformation trends in the domestic pharmaceutical equipment industry [3] - The company aims to enhance the proportion of international business in its revenue and build a global high-end pharmaceutical equipment brand through innovation and product refinement [3]

Core Viewpoint - The Shandong Provincial Department of Commerce has announced the first batch of leading enterprises in integrated domestic and foreign trade, with Shandong New Era Pharmaceutical Co., Ltd. recognized as a key enterprise for cultivation in this initiative [1] Group 1: Integrated Trade Development - The recognition is part of efforts to promote integrated domestic and foreign trade reform and to foster deep integration of these markets, contributing to the establishment of a new development pattern in the province [1] - The initiative aims to cultivate a number of internationally competitive leading enterprises and industry clusters that balance both domestic and foreign trade [1] Group 2: Company Strategy - Shandong New Era Pharmaceutical Co., Ltd. aims to position itself as a market leader in integrated domestic and foreign trade, continuously demonstrating its role as a model enterprise [1] - The company is committed to compliance management and maintaining high-quality standards while pursuing internationalization strategies [1] - Plans include developing a "Traditional Chinese Medicine Innovation Corridor" targeting South Asia and Southeast Asia, as well as accelerating the registration of biopharmaceuticals in the European and American markets to enhance export value [1]

Group 1 - The core point of the news is that Huahai Pharmaceutical's stock has experienced a decline, with a 5.65% drop over the last three days, closing at 17.55 yuan per share on January 14, with a total market capitalization of 26.277 billion yuan [1] - Huahai Pharmaceutical, established on February 28, 2001, and listed on March 4, 2003, specializes in the research, production, and sales of various dosage forms of generic drugs, biological drugs, innovative drugs, and specialty raw materials [1] - The company's revenue composition includes finished drug sales at 61.86%, raw materials and intermediates sales at 36.75%, other sales at 0.78%, and technical services at 0.62% [1] Group 2 - From the perspective of major fund holdings, one fund under Qianhai United Fund holds Huahai Pharmaceutical as its eighth largest position, with 40,000 shares representing 3.38% of the fund's net value [2] - The fund, Qianhai United National Health Mixed A (003581), has incurred a floating loss of approximately 5,600 yuan today and a total floating loss of 42,000 yuan during the three-day decline [2] - The fund was established on December 29, 2016, with a latest scale of 15.6476 million yuan, and has achieved a year-to-date return of 9.78% [2]

Economic Development and Key Industries - Yunnan Province emphasizes high-quality development and project work to drive economic growth, focusing on nine major initiatives [1] - Since the 14th Five-Year Plan, Yunnan has held 16 consecutive quarterly meetings to promote major industrial projects, leading to significant investment and project completion [4] - The province achieved a 39.22% support rate for overall investment, with private enterprise projects completing 86.36% of their annual investment plans [6] Project Implementation and Investment - Yunnan has successfully completed 102.67% of the annual investment plan for 72 key projects and 104.08% for 832 infrastructure projects [6] - The provincial government is concentrating on project-driven growth to enhance the real economy and establish a modern industrial system with Yunnan characteristics [8] Social Welfare and Insurance Initiatives - Yunnan is implementing a long-term care insurance system to support individuals with disabilities, with varying fund payment ratios based on employment status [11][13] - The province has announced an increase in living and care subsidies for disabled individuals, effective January 1, 2026, raising monthly support for certain categories of disabilities [16] Industry-Specific Developments - The nut industry in Yun County is projected to exceed 820 million yuan in output by 2025, with significant growth in planting area and production [23] - A national-level biopharmaceutical pilot platform has been launched in Kunming to enhance the biopharmaceutical industry's capabilities [25] - The first water asset securitization project in Qujing has been successfully established, marking a significant financial innovation in the region [26] - The first complete cost insurance for coffee cultivation has been implemented in Pu'er, providing substantial risk coverage for local farmers [27]

Core Viewpoint - Kanghong Pharmaceutical has shown a positive stock performance with a year-to-date increase of 13.65% and a market capitalization of 31.38 billion yuan as of January 9 [1]. Financial Performance - For the period from January to September 2025, Kanghong Pharmaceutical achieved a revenue of 3.624 billion yuan, representing a year-on-year growth of 6.23%. The net profit attributable to shareholders was 1.033 billion yuan, with a year-on-year increase of 6.08% [2]. Shareholder Information - As of December 31, the number of shareholders for Kanghong Pharmaceutical reached 28,900, an increase of 1.32% from the previous period. The average number of circulating shares per shareholder decreased by 1.30% to 23,805 shares [2]. Dividend Distribution - Since its A-share listing, Kanghong Pharmaceutical has distributed a total of 2.038 billion yuan in dividends, with 1.04 billion yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, the fourth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 28.007 million shares, an increase of 730,000 shares from the previous period. Other notable shareholders include Dachen Rui Xiang Mixed A and Dachen Competitive Advantage Mixed A, which saw reductions in their holdings [3].